To The Moon

Thinking about what to do with Pfizer stock right now? You’re not alone, and frankly, it’s been a fascinating ride. After lagging for much of the past three years, Pfizer’s share price has shown a subtle change in mood lately. The stock edged up 1.3% over the last week and 3.4% this past month, which might catch your eye, especially after a rocky year marked by a -6.6% dip year-to-date and a -7.8% slide over the last twelve months. Those numbers might look daunting, but every story has more than one chapter. There’s more at play than just sentiment. Key partnerships on new drug development and several pipeline updates have provided fresh optimism, hinting at growth potential beyond the COVID era. Yet, the shadow of long-term underperformance lingers, with the stock down nearly 36% over thr

$Netflix(NFLX)$ Netflix (NASDAQ: NFLX) shares tumbled over 6% in after-hours trading following a disappointing third-quarter earnings report that fell well short of Wall Street expectations. Despite solid subscriber growth, a one-time tax hit in Brazil, higher content amortization expenses, and trimmed full-year guidance weighed heavily on investor sentiment. Now, the key question for investors: is this post-earnings plunge an opportunity to buy the dip — or the start of a bigger unwind? Q3 Earnings: Profit Misses, Tax Hit from Brazil Netflix reported third-quarter revenue of $9.36 billion, up 12% year-over-year, slightly ahead of consensus estimates. However, net income came in sharply lower than expected at $1.14 billion, translating to earnings